Skip to main
GLUE
GLUE logo

GLUE P/E Ratio

P/E Ratio as of Jul 3, 2025: 72.47

Average70.62
Median69.87
Minimum66.82
Maximum75.60
72.47
Past Month+5.51 (8.23%)
The P/E ratio for GLUE is 72.47 as of Jul 3, 2025. This represents a increase of 773.13% compared to its 12-month average P/E ratio of 8.3. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.

Monte Rosa Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)

Monte Rosa Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Monte Rosa Therapeutics to industry peers.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

GLUE P/E Ratio Historic Data

DateStock priceP/E ratio
Jul 1, 2025$4.6168.60
Jun 2, 2025$4.5066.96
May 1, 2025$4.90-4.76
Apr 1, 2025$4.43-4.30
Mar 3, 2025$5.55-3.03
Feb 3, 2025$6.51-3.55
Jan 2, 2025$7.11-3.88

GLUE End of Year P/E Ratio

DateP/E ratioChange
202572.47-2,012.14%
2024-3.79+80.48%
2023-2.10-40.17%
2022-3.51-72.12%
2021-12.59

FAQs About Monte Rosa Therapeutics (GLUE) P/E ratio

The latest P/E ratio of GLUE is 72.47, as of Jul 3, 2025. This is calculated based on its current stock price and earnings per share (EPS).

Monte Rosa Therapeutics’s last 12-month average P/E ratio is 8.3, compared to its current P/E ratio of 72.47. This reflects a increase of 773.13%.

Monte Rosa Therapeutics’s current P/E ratio of 72.47 is higher than its last 12-month average P/E of 8.3. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.

Monte Rosa Therapeutics’s average P/E ratio over the last 3 years is 0.97. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.

Monte Rosa Therapeutics’s average P/E ratio over the last 5 years is -0.5. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.

Monte Rosa Therapeutics (GLUE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.